Tyra Bioscience, Inc (TYRA)

Tyra Biosciences' stock has increased significantly in the past six months. The announcement of the first patient dosed in the Phase 2 SURF302 clinical trial of TYRA-300 led to a positive market reaction. The company reported its Second Quarter 2025 financial results, highlighting progress in clinical trials and a cash runway projected through at least 2027. The first child was dosed in BEACH301, its Phase 2 study for dabogratinib in pediatric achondroplasia. Oppenheimer maintained a "Buy" rating on TYRA stock with a price target of $36.00. The company released its Third Quarter 2025 financial results, reporting ongoing enrollment in its BEACH301 and SURF302 Phase 2 studies. Tyra Biosciences announced the strengthening of its leadership team with new appointments. Wedbush raised its price target for Tyra Biosciences to $37.00 from $30.00, maintaining an "Outperform" rating. Insider selling activity has been observed in the past three months.

Tyra Biosciences, Inc. does not currently generate revenue from the sale of commercial products, therefore, traditional demand seasonality is not applicable at this stage of its development.

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation precision medicines. Operating in the Healthcare sector, specifically in the Biotechnology industry, the company targets oncology and genetically defined conditions. Tyra Biosciences utilizes its proprietary SNÅP platform to design selective kinase inhibitors to overcome acquired resistance mechanisms in targeted therapies. Its clinical pipeline includes TYRA-300 (dabogratinib) for pediatric achondroplasia, low-grade IR NMIBC, LG-UTUC, and mUC; TYRA-200 for FGFR2+ cancers; TYRA-430 for advanced HCC and other solid tumors; and TYRA-305 for various fibrotic diseases.

Tyra Biosciences, Inc. is headquartered in Carlsbad, California, United States. While its primary operations are based in the U.S., its clinical trials are designed to enroll patients at multiple sites across the globe.

Tyra Biosciences has maintained a generally positive brand reputation over the past year, driven by its scientific advancements, clinical trial progress, and active engagement within the biotechnology and investment communities. The company's participation in healthcare and investor conferences has enhanced its visibility and scientific credibility. The strengthening of its leadership team contributes positively to its corporate image. Positive analyst coverage and increased price targets reflect a favorable perception of the company's potential. Tyra Biosciences' mission to develop precision medicines fosters a positive reputation among patient communities and the medical field.

Tyra Biosciences, Inc. has significant institutional ownership, with 250 institutional owners and shareholders holding a total of 57,350,581 shares, representing 62.04% of the company's stock. Nina S. Kjellson is the largest individual shareholder, owning 8.33 million shares, representing 15.61% of the company. Other significant insider owners include Boxer Capital LLC, Boxer Capital Management LLC, Alta Partners Nextgen Fund II Management LLC, and Robert J. More.